Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
 |
Open Access Gold |
|
as soon as is submitted to ZB.
Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab.
Acta Derm.-Venereol. 96, 72-76 (2016)
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Atopic Dermatitis ; Atopic Eczema ; Immunoglobulin E ; Ige ; Immunoadsorption ; Omalizumab ; Anti-ige-treatment; Activation-regulated Chemokine; Food Allergy; Liver-transplantation; Therapy; Disease; Urticaria; Efficacy; Thymus
ISSN (print) / ISBN
0001-5555
e-ISSN
1651-2057
Journal
Acta Dermato-Venereologica
Quellenangaben
Volume: 96,
Issue: 1,
Pages: 72-76
Publisher
Acta Dermato-Venereologica
Publishing Place
Uppsala
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute for Allergy Research (IAF)